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Dengue diseases have an economic as well as social burden worldwide. In this study, the antiviral activity of protegrin-1 (PG-1,
RGGRLCYCRRRFCVCVGR) peptide towards dengue NS2B-NS3pro and viral replication in Rhesus monkey kidney (MK2) cells
was investigated. The peptide PG-1 was synthesized by solid-phase peptide synthesis, and disulphide bonds formation followed by
peptide purification was confirmed by LC-MS and RPHPLC. Dengue NS2B-NS3pro was produced as a single-chain recombinant
protein in E. coli. The NS2B-NS3pro assay was carried out by measuring the florescence emission of catalyzed substrate. Real-time
PCR was used to evaluate the inhibition potential of PG-1 towards dengue serotype-2 (DENV-2) replication in MK2 cells. The
results showed that PG-1 inhibited dengue NS2B-NS3pro at IC50 of 11.7 μM. The graded concentrations of PG-1 at nontoxic
range were able to reduce viral replication significantly (P < 0.001) at 24, 48, and 72 hrs after viral infection. However, the
percentage of inhibition was significantly (P < 0.01) higher at 24 hrs compared to 48 and 72 hrs. These data show promising
therapeutic potential of PG-1 against dengue infection, hence it warrants further analysis and improvement of the peptide features
as a prospective starting point for consideration in designing attractive dengue virus inhibitors.
1. Introduction
Dengue infection causes various clinical symptoms ranging
from mild fever to severe hemorrhagic fever and dengue
shock syndrome [1–3]. The virus uses host cell ribosomes to
translate its genomic RNA to full-length precursor polypro-
tein. Subsequently, the host cell furin and dengue NS2B-
NS3 serine protease (NS2B-NS3pro) cleave viral polyprotein
at various regions to produce structural and nonstructural
viral proteins [4–6]. The NS3 protein is one of the viral non-
structural proteins that possess enzymatic activities. The N-
terminal of this protein contains 180 amino acid residues
that represent NS3 protease [7, 8], while C-terminal region
contains amino acid residues that represent RNA helicase
and RNA-stimulated NTPase [9, 10]. The activity of NS2B-
NS3pro depends on the interaction with its cofactor NS2B
to form a NS2B-NS3pro complex [11]. It has been found
that the disruption of NS2B-NS3pro functions inhibits viral
replication [12]. Therefore, NS2B-NS3pro is considered as a
potential target for the design of antiviral drugs [13].
At present, a legitimate vaccine or treatment to prevent or
to cure this disease is unavailable [14]. These facts emphasize
the need for a better understanding of the mechanism of
viral infection and propagation in the host cell to combat
this disease. Recently, computational studies indicated that
cationic cyclic peptides have potential inhibition towards
dengue NS2B-NS3pro [15, 16]. Protegrin-1 (PG-1, RGGRL-
CYCRRRFCVCVGR) is an eighteen amino acids cationic
cyclic peptide with high content of basic residues and two
disulphide bonds. The peptide is originally isolated from
porcine white blood cells and considered as an antibiotic
agent against a broad range of microorganisms [17, 18]. The
formation of two disulphide bonds between cysteine residues
endows PG-1 with a stabile β-hairpin secondary structure
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that is crucial for antimicrobial activity [19, 20]. Therefore,
removal of these two disulphide bonds is found to noticeably
reduce the antimicrobial activity of PG-1 [21]. The peptide
is able to penetrate and disrupt the cell membrane by
homodimerization [22, 23]. The mechanism of this activity
depends on the secondary structure and the cationic nature
of PG-1 molecules which are essential to generate pores
in the cell membrane of microorganism [24–27]. In this
study, our objective was to examine the eﬃcacy of PG-1 as
cationic cyclic peptide to inhibit dengue serine protease and
subsequently reduce viral replication in host cells.
2. Methods
2.1. Synthesis of Cyclic PG-1. The linear peptides were
prepared by automated peptide synthesis using Symphony
parallel synthesizer (Protein Technologies, Tucson, AZ, USA)
by standard solid-phase peptide synthesis. The crude pep-
tides were lyophilized before proceeding to folding experi-
ments. The lyophilized peptide was dissolved in 20% DMSO
solution in a round bottom flask and stirred on a magnetic
stirrer to produce a peptide concentration of 1.1mM. The
progress of the reaction was monitored by HPLC and LCMS.
The formation of the first disulphide bond was completed
within 24 hrs. The solution was then lyophilized to proceed
for second disulfide formation. The lyophilized peptide with
the first disulphide bond was dissolved in acetic acid water
(4 : 1) so that the peptide concentration was 1.2mM and
iodine (10 equivalents) was added in one portion. The
reactions were stirred at 25◦C for 60min and then quenched
by diluting with water and extracting with CCl4 to remove
excess iodine. The aqueous phase was then lyophilized to
give the crude peptide. The identity of the crude peptide
was confirmed by LC-MS. Purification of crude cyclised
peptide was accomplished by RP-HPLC (Agilent 1200 series).
The identity of the purified peptide with 98% purity was
confirmed by LC-MS (Shimadzu LC/MS 2020, single quad).
2.2. Production of NS2B-NS3pro in E. coli. To produce single
chain protease NSB2- (G4-T-G4)-NS3, the NS2B fragments
were amplified individually by PCR using the primer pairs
NS2B-F (5′-ATACTGAGGATCC GCCGATTTGGAACTG-
3′) and NS2Blinker-R (ACCTACTAGGTACCTCCT-
CCACCCAGTGTCTGTTCTTC). The NS2B-NS3 was
amplified by NS3linker-F (5′-ATCTATAGGTACCGGC-
GGTGGAGGTGCTGGAGTATTGTGG-3′) and NS3-R
(5′-AGCATAAGCTTAAGCTTCAATTTTCT-3′). The linker
sequence was added to NS2Blinker-R and NS3linker-F
primers which included the site for KpnI restriction enzyme
(all restriction sites are underlined). The PCR product of
NS2B fragment was digested with BamHI and KpnI while
NS2B fragment was digested with KpnI and HindIII. Purified
fragments were cloned into pQE30 plasmid downstream
of 6×His tag. The Escherichia coli X-blue strain (Promega,
USA) was transformed with pQE30-cNSB -(G4TG4)-NS3
plasmid. The recombinant E. coli was inoculated in Luria-
Bertani liquid medium (1% tryptone, 1% NaCl, 0.5%
yeast extract, w/v, pH 7.0) supplemented with 100mg/L
ampicillin and cultured overnight at 37◦C. In brief, 10ml of
overnight grown culture was added to 1000mL of medium
and incubated with shaking at 37◦C until the optical density
at 600 nm reached 0.5. Subsequently, isopropylthio-β-D-
galactoside (IPTG) was then added to a final concentration of
0.5mM and the bacteria were cultured for an additional 5 hrs
at 37◦C in a shaking incubator to induce protein expression.
Finally, bacterial cells were harvested by centrifugation at
4000 rpm for 15min at 4◦C.
2.3. Protein Purification. The recombinant NS3pro was
produced as soluble proteins and, therefore, the purification
had been performed by His GraviTrap Flow precharged
Ni Sepharose 6 Fast column (Amersham Biosciences, USA)
according to the manufacturer’s instructions. In brief, the
column was normalized with phosphate buﬀer (20mM
sodium phosphate buﬀer and 500mM NaCl, pH 7.4). The
sample was loaded into the column and the column was
washed with binding buﬀer (phosphate buﬀer containing
20mM imidazole, pH 7.4). The recombinant protein was
eluted with elution buﬀer (phosphate buﬀer containing
200mM imidazole, pH 7.4). Further purification was applied
using gel aﬃnity chromatography to achieve more than 95%
purity.
2.4. Protease Assay. The bioassay used in this study was
modified from the method published by Kiat and coworkers
[28]. Reaction mixtures with total volume of 200 μL were
prepared. These reaction mixtures consisted of 100 μM flu-
orogenic peptide substrate (Boc-Gly-Arg-Arg-MCA), 2 μM
NS2B-NS3pro complex, with or without PG-1 of varying
concentrations, buﬀered at pH 8.5 with 200mM Tris-
HCl. The PG-1 was initially prepared in Tris-HCl buﬀer
and assayed at five diﬀerent concentrations. The reaction
mixtures without fluorogenic peptide substrate were firstly
incubated at 37◦C for 30 minutes. Subsequently, the sub-
strate was added and themixture was further incubated at the
same temperature for 30minutes. Triplicates were performed
for all measurements and the readings were taken using
Tecan Infinite M200 Pro fluorescence spectrophotometer.
Substrate cleavage was optimized at the emission at 440 nm
upon excitation at 350 nm. The readings were then used for
calculating Km values of peptide substrate and IC50 values
of peptide inhibitors using nonlinear regression models in
GraphPad Prism 5.01 software.
2.5. Maximum Nontoxic Dose Test (MNTD). The MK2 cell
lines were seeded at 1 × 104 cells per well in triplicate at
optimal conditions (37◦C, 5% CO2 in humidified incubator)
in 96 well plates. PG-1 was diluted to serial concentrations
2.5, 12.5, 25, 50, 100 and 200 μM with DMEM media sup-
plemented with 2% FBS. The cell culture was analyzed at 24,
48 and 72 hours using nonradioactive cell proliferation assay
(Promega, USA) according to the manufacture protocol.
2.6. Treatment of DENV-2-Infected Cells with PG-1 Peptide.
The MK2 cell lines were grown in a 24-well tissue culture
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Figure 1: Production of single chain protease NSB2- (G4-T-G4)-NS3pro in E. coli. (a) The recombinant NS2B-NS3pro was produced as
soluble proteins and purified by nickel column. L1: cell lysate, L2: washing flow through, L3: elution 1, and L4: elution 2. (b) Further
purification was applied using gel aﬃnity chromatography (95% of enzyme purity) L1 to L4: Elution 1 to 4. The activity of purified enzyme
was assessed by catalyzing the fluorogenic peptide substrate (Boc-Gly-Arg-Arg-MCA).
plate (1 × 105 cells/well), incubated 24 hrs under optimal
conditions (37◦C and 5% CO2). DENV-2 was added to the
wells (MOI of 2) followed by incubation for 1 hr with gentle
shaking every 10min for optimal virus to cell contact. The
virus supernatant was removed, and the cells were washed
twice with fresh serum free DMEMmedia to remove residual
virus. New complete DMEM media containing 2.5, 7.5 and
12.5 μM of PG-1 were added and the cultures were incubated
for 24, 48 and 72 hrs. Afterwards, cellular supernatants were
collected and stored at−80◦C for viral quantification by real-
time PCR.
2.7. Real-Time PCR. For quantification of DENV-2 copies,
the standard curve was generated by 10-fold serial dilu-
tion of known copies of DENV-2 RNA. Viral RNA was
extracted from culture supernatant using QIAmp viral RNA
minikit (QIAGEN, Germany) according to the manufac-
turer’s instructions. A fragment located at the 5′UTR region
of the virus genome was used to generate the primers.
One-step RT-PCR using SyBr Green Master Kit (Qiagen,
Germany) was used to conduct absolute quantification using
ABI7300 machine from Applied Biosystems (Foster City,
CA). The PCR programme included 1 cycle of 50◦C for
2min, 1 cycle of 95◦C for 10min, and 40 cycles of 95◦C
for 15 sec and 60◦C for 1min. Dissociation curve analysis
was added to the end of each run. Results were analyzed
using Sequence Detection Software Version 1.3 (Applied
Biosystems, Foster City, CA, USA).
2.8. Statistical Analysis. All the assays were done in triplicates
and the statistical analyses were performed using GraphPad
Prism version 5.01 (GraphPad Software, San Diego, CA).
P values <0.05 were considered significant. Error bars are
expressed as ± SD.
Table 1: The parameters of PG-1 Inhibition potential towards
NS2B-NS3pro.
Parameter∗ Values Std. Error
Vmax 0.28 μmol/min ±0.01
Alpha 3.14 ±0.81
Ki 5.85 μM ±1.82
IC50 11.70 μM ±2.23
Km 109.10 μM ±7.50
∗Vmax: maximum enzyme velocity (μmol/min). Km: Michaelis-Menten
constant (μM). Ki: inhibition constant (μM). Alpha: constant that deter-
mines mechanism. If alpha = 1, this is the same as noncompetitive. If alpha
is very high, then the model approaches a competitive model. If alpha is very
low (but greater than zero), the model approaches an uncompetitive model.
All parameters were calculated by GraphPad Prism 5.0 software.
3. Results and Discussion
The recombinant NS2B-NS3pro was produced as a sol-
uble protein in E. coli and purified by nickel column
(Figure 1(a)). Further purification was applied using gel
aﬃnity chromatography to achieve more than 95% of
enzyme purity (Figure 1(b)). The activity of purified enzyme
had been assessed at 37◦C by catalyzing the fluoro-
genic peptide substrate t-Butyloxycarbonylglycyl-L-arginyl-
L-arginyl-L-4-methylcoumaryl-7-amide (Boc-Gly-Arg-Arg-
MCA). The PG-1 peptide was added to the protease reaction
at diﬀerent concentrations and the inhibition profile was
plotted as shown in Figure 2.
It was observed that the inhibition potential increased
with PG-1 concentration and the highest inhibition (95.7%)
with low concentrations of PG-1 was at 40 μM. The kinetic
assay study indicated that PG-1 competitively inhibited
NS2B-NS3pro activity (alpha value 3.14) with Ki value
5.85 μM(Table 1). Intriguingly, the maximum enzyme veloc-
ity decreased threefold when PG-1 concentration was 20 μM
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Figure 2: Dengue protease inhibition assay. The reaction mixtures
consisted of fluorogenic peptide substrate and NS2B-NS3pro, with
or without PG-1 of varying concentrations. The PG-1 was initially
prepared in Tris-HCl buﬀer and assayed at five diﬀerent concen-
trations, 10–160 μM. The best inhibition with low concentration of
PG1 was observed at 40 μM with 95.7% inhibition.
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Figure 3: Kinetic assay plot for the inhibition of the NS2B-NS3pro
from dengue virus by PG-1 peptide. This assay was carried out using
increasing concentration of inhibitor while all other conditions
were kept constant. The data was analysed by Michaelis-Menten
model under nonlinear regression curve fit in GraphPad Prism 5
software. The peptide concentrations were 0, 2.5, 5, 10, and 20 μM.
The maximum enzyme velocity decreased from approximately
threefold when PG-1 concentration was 20 μM.
(Figure 3). Previous studies have shown that various types of
natural and chemical compounds were able to inhibit dengue
NS2B-NS3pro activity. For example, some of plant natural
compounds, such as Chalcones, have shown good inhibition
potential against the dengue protease (Ki value 21–25 μM)
[28]. The synthesized peptidic α-keto-amide compound
inhibited dengue NS2B-NS3pro with Ki value of 47 μM [29].
Most recent study indicated that the retrotripeptides with
an arylcyanoacrylamide group as N-terminal cap exhibited
high inhibition potential against dengue protease with Ki
value of 4.6 μM [30]. Most recent study showed that the
inhibition potential of some chemical compounds towards
NS2B-NS3pro measured by IC50 was 15.4, 20.4, and 27.0 μM
[31].
0
10
20
30
40
50
60
70
80
90
100
2.5 12.5 25 50 100 200
To
xi
ci
ty
 (
%
)
24 hrs
48 hrs
72 hrs
Concentrations of PG-1 (µM)
Figure 4: Maximum nontoxic dose (MNTD) of PG-1.TheMK2 cell
lines were seeded at 1 × 104 cells per well in triplicate at optimal
conditions (37◦C, 5% CO2 in humidified incubator) in 96 well
plates. PG-1 was diluted to serial concentrations 2.5, 12.5, 25, 50,
100, and 200 μM with DMEM media supplemented with 2% FBS.
The cell culture was analyzed at 24, 48, and 72 hrs using Non-
Radioactive Cell Proliferation assay (Promega, USA) according
to the manufacture protocol. The toxic dose of MK2 cells was
identified to be greater than 12.5 μM.
Cytotoxicity and compound stability can be considered
as major limitations of the practical application of protease
inhibitors. In this study, to test PG-1 toxicity, MK2 cell
lines were incubated with increasing concentrations of PG-
1 for 24, 48, and 72 hrs. The PG-1 peptide showed toxic
eﬀect against MK2 cell lines at concentrations greater than
12.5 μM (Figure 4). Other studies indicated that PG-1 was
also toxic to 293A cell lines (human embryonic kidney cells)
at 50 μg/ml (25 μM) [32] and more than 50% of human red
blood cells lyses were observed at 80 μg/ml (40 μM) [33].
Therefore, three concentrations at nontoxic range were used
to test PG-1 stability and ability to reduce dengue viral
replication in MK2 cell lines. The results showed that the
viral copy number significantly (P < 0.001) reduced with
increasing concentrations of PG-1 (Figure 5(a)). Further-
more, the highest inhibition percentage was observed when
the PG-1 concentration was 12.5 μM at 24, 48 and 72 hrs
(Figure 5(b)). However, the low concentrations exhibited
less inhibition percentage at 48 and 72 hrs as compared
with 24 hrs, indicating that the PG-1 stability declined with
longer incubation in culture media (Figures 5(a) and 5(b)).
Similarly, it has been showed that at low doses (4 μg/ml),
PG-1 has significant in vitro antimicrobial activity with low
in vivo toxicity (up to 8mg/kg i.v. mouse injection) [34].
This may be accounted by its short half-life in vivo as its
level in mice plasma that was injected with 4mg/ml i.v.
declined rapidly to 28 μg/ml after 5min [34]. Although PG-1
showed significant inhibition profile towards dengue virus in
this study and to human immunodeficiency virus 1 (HIV1)
in another study [35], the peptide instability should be
considered as a major concern. The results in this study may
give a clear picture that would then help in engineering new
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Figure 5: RNA quantification and the percentage of inhibition after applying diﬀerent concentrations of PG-1 onMK2 cell lines infected with
dengue virus. The standard curve was generated by 10-fold serial dilution of known copies of dengue RNA. Viral RNA was extracted from
cellular supernatant and the fragment located at the 5′UTR region of the virus genome was amplified using one-step RT-PCR. Significant
reduction (P < 0.001) in viral copy number was observed with increasing PG-1 concentration (a). The highest inhibition percentage was
observed with 12.5 μM at 24, 48, and 72 hrs (b). PG-1 significantly (P < 0.01) inhibited DENV-2 replication in a dosedependent manner
with the greatest inhibition eﬀects at 24 hrs (two-way ANOVA with Bonferroni posttest, mean ± SD).
sequence of peptides to retain the antiviral activity against
dengue while increasing its stability and eliminating the toxic
characteristics of PG-1.
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